Ignite Creation Date:
2025-12-24 @ 5:45 PM
Ignite Modification Date:
2025-12-27 @ 7:12 PM
Study NCT ID:
NCT06397768
Status:
ACTIVE_NOT_RECRUITING
Last Update Posted:
2025-01-14
First Post:
2024-04-29
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'interventionBrowseModule': {'meshes': [{'id': 'C061529', 'term': 'YM 534'}, {'id': 'D013745', 'term': 'Tetanus Toxoid'}, {'id': 'D017325', 'term': 'Hepatitis B Vaccines'}, {'id': 'C000617220', 'term': 'Vaxelis'}, {'id': 'D023321', 'term': 'Poliovirus Vaccines'}, {'id': 'C512971', 'term': 'pentacel'}, {'id': 'C075655', 'term': 'Recombivax HB'}, {'id': 'D022242', 'term': 'Pneumococcal Vaccines'}, {'id': 'D022243', 'term': 'Rotavirus Vaccines'}, {'id': 'C492535', 'term': 'RotaTeq'}, {'id': 'D022542', 'term': 'Measles-Mumps-Rubella Vaccine'}, {'id': 'D053061', 'term': 'Herpes Zoster Vaccine'}, {'id': 'D019433', 'term': 'Chickenpox Vaccine'}], 'ancestors': [{'id': 'D014121', 'term': 'Toxoids'}, {'id': 'D014612', 'term': 'Vaccines'}, {'id': 'D001688', 'term': 'Biological Products'}, {'id': 'D045424', 'term': 'Complex Mixtures'}, {'id': 'D014761', 'term': 'Viral Hepatitis Vaccines'}, {'id': 'D014765', 'term': 'Viral Vaccines'}, {'id': 'D022541', 'term': 'Streptococcal Vaccines'}, {'id': 'D001428', 'term': 'Bacterial Vaccines'}, {'id': 'D017778', 'term': 'Vaccines, Combined'}, {'id': 'D008458', 'term': 'Measles Vaccine'}, {'id': 'D009108', 'term': 'Mumps Vaccine'}, {'id': 'D012411', 'term': 'Rubella Vaccine'}, {'id': 'D022283', 'term': 'Herpesvirus Vaccines'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE3'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'RANDOMIZED', 'maskingInfo': {'masking': 'TRIPLE', 'whoMasked': ['PARTICIPANT', 'CARE_PROVIDER', 'OUTCOMES_ASSESSOR'], 'maskingDescription': '* Blinding for vaccine group assignment: participants, parents or legally acceptable representatives (LAR) and laboratory personnel at the Sponsor\n* No blinding for study staff who prepare and administer the study interventions, investigators or Sponsor study staff'}, 'primaryPurpose': 'PREVENTION', 'interventionModel': 'PARALLEL'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 2226}}, 'statusModule': {'overallStatus': 'ACTIVE_NOT_RECRUITING', 'startDateStruct': {'date': '2024-05-13', 'type': 'ACTUAL'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2025-01', 'completionDateStruct': {'date': '2025-09-30', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2025-01-13', 'studyFirstSubmitDate': '2024-04-29', 'studyFirstSubmitQcDate': '2024-04-29', 'lastUpdatePostDateStruct': {'date': '2025-01-14', 'type': 'ACTUAL'}, 'studyFirstPostDateStruct': {'date': '2024-05-03', 'type': 'ACTUAL'}, 'primaryCompletionDateStruct': {'date': '2025-09-30', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'RSV A serum neutralizing antibody titers at 28 days post dose 2 (D85) Groups 1 and 3', 'timeFrame': 'Day 85', 'description': 'Antibody titers at Day 85'}, {'measure': 'RSV B serum neutralizing antibody titers at 28 days post dose 2 (D85) Groups 1 and 3', 'timeFrame': 'Day 85', 'description': 'Antibody titers at Day 85'}, {'measure': 'RSV A serum neutralizing antibody titers at Day 113 Groups 2 and 4', 'timeFrame': 'Day 113', 'description': 'Antibody titers at Day 113'}, {'measure': 'RSV B serum neutralizing antibody titers at Day 113 Groups 2 and 4', 'timeFrame': 'Day 113', 'description': 'Antibody titers at Day 113'}], 'secondaryOutcomes': [{'measure': 'Anti- hepatitis B surface antigen (HBsAg) Immunoglobulin g (IgG) antibody (A)b concentrations ≥ 10 milli international units per milliliter (mIU/mL) Cohort 1', 'timeFrame': '28 days after the 6 month routine vaccinations', 'description': 'Antibody titers 28 days after the 6 month routine vaccinations'}, {'measure': 'Anti- polyribosylribitol phosphate (PRP) Ab concentrations ≥ 0.15 micrograms per milliliter (µg/mL) Cohort 1', 'timeFrame': '28 days after the 6 month routine vaccinations', 'description': 'Antibody titers 28 days after the 6 month routine vaccinations'}, {'measure': 'Anti-poliovirus types (1, 2, and 3) Ab titers ≥ 1:8 Cohort 1', 'timeFrame': '28 days after the 6 month routine vaccinations', 'description': 'Antibody titers 28 days after the 6 month routine vaccinations'}, {'measure': 'Anti-pertussis Ab concentrations pertussis toxin, filamentous hemagglutinin , pertactin, fimbriae (PT, FHA, PRN, FIM) Cohort 1', 'timeFrame': '28 days after the 6 month routine vaccinations', 'description': 'Antibody titers 28 days after the 6 month routine vaccinations'}, {'measure': 'Anti-diphtheria Ab concentrations ≥ 0.1 IU/mL Cohort 1', 'timeFrame': '28 days after the 6 month routine vaccinations', 'description': 'Antibody titers 28 days after the 6 month routine vaccinations'}, {'measure': 'Anti-tetanus Ab concentrations ≥ 0.1 IU/mL Cohort 1', 'timeFrame': '28 days after the 6 month routine vaccinations', 'description': 'Antibody titers 28 days after the 6 month routine vaccinations'}, {'measure': 'Anti-pneumococcal Ab concentrations measured by electrochemiluminescence (ECL) for serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F and 33F Cohort 1', 'timeFrame': '28 days after the 6 month routine vaccinations', 'description': 'Antibody titers 28 days after the 6 month routine vaccinations'}, {'measure': 'Anti-measles Ab concentrations ≥ 255 mIU/mL Cohort 2', 'timeFrame': '28 days after the 12 month routine vaccinations', 'description': 'Antibody titers 28 days after the 12 month routine vaccinations'}, {'measure': 'Anti-mumps Ab concentrations ≥ 10 antibody units (AbU/mL) Cohort 2', 'timeFrame': '28 days after the 12 month routine vaccinations', 'description': 'Antibody titers 28 days after the 12 month routine vaccinations'}, {'measure': 'Anti-rubella Ab concentrations ≥ 10 IU/mL Cohort 2', 'timeFrame': '28 days after the 12 month routine vaccinations', 'description': 'Antibody titers 28 days after the 12 month routine vaccinations'}, {'measure': 'Anti-varicella Ab concentrations ≥ 5 glycoprotein enzyme-linked immunosorbent assay (gpELISA) units/mL Cohort 2', 'timeFrame': '28 days after the 12 month routine vaccinations', 'description': 'Antibody 28 days after the 12 month routine vaccinations'}, {'measure': 'Anti-pneumococcal Ab concentrations measured by ECL Cohort 2', 'timeFrame': '28 days after the 12 month routine vaccinations', 'description': 'Antibody titers 28 days after the 12 month routine vaccinations'}, {'measure': 'Descriptive: Anti-PRP Ab concentrations (µg/mL) Cohort 1', 'timeFrame': '28 days after the 6 month routine vaccinations', 'description': 'Antibody titers 28 days after the 6 month routine vaccinations'}, {'measure': 'Descriptive: Anti-diphtheria Ab concentrations (IU/mL) Cohort 1', 'timeFrame': '28 days after the 6 month routine vaccinations', 'description': 'Antibody titers 28 days after the 6 month routine vaccinations'}, {'measure': 'Descriptive: Anti-diphtheria Ab concentrations ≥ 0.01 IU/mL Cohort 1', 'timeFrame': '28 days after the 6 month routine vaccinations', 'description': 'Antibody titers 28 days after the 6 month routine vaccinations'}, {'measure': 'Descriptive: Anti-tetanus Ab concentrations (IU/mL) Cohort 1', 'timeFrame': '28 days after the 6 month routine vaccinations', 'description': 'Antibody titers 28 days after the 6 month routine vaccinations'}, {'measure': 'Descriptive: Anti-tetanus Ab concentrations ≥ 0.01 IU/mL Cohort 1', 'timeFrame': '28 days after the 6 month routine vaccinations', 'description': 'Antibody titers 28 days after the 6 month routine vaccinations'}, {'measure': 'Descriptive: Anti-HBsAg Ab concentrations (mIU/mL) Cohort 1', 'timeFrame': '28 days after the 6 month routine vaccinations', 'description': 'Antibody titers 28 days after the 6 month routine vaccinations'}, {'measure': 'Descriptive: Anti-HBsAg Ab concentrations ≥ 100 mIU/mL Cohort 1', 'timeFrame': '28 days after the 6 month routine vaccinations', 'description': 'Antibody titers 28 days after the 6 month routine vaccinations'}, {'measure': 'Descriptive: Anti-poliovirus types (1, 2, and 3) Ab titers Cohort 1', 'timeFrame': '28 days after the 6 month routine vaccinations', 'description': 'Antibody titers 28 days after the 6 month routine vaccinations'}, {'measure': 'Descriptive: Anti-measles Ab concentrations (mIU/mL) Cohort 2', 'timeFrame': '28 days after the 12 month routine vaccinations', 'description': 'Antibody titers 28 days after the 12 month routine vaccinations'}, {'measure': 'Descriptive: Anti-mumps Ab concentrations (AbU/mL) Cohort 2', 'timeFrame': '28 days after the 12 month routine vaccinations', 'description': 'Antibody titers 28 days after the 12 month routine vaccinations'}, {'measure': 'Descriptive: Anti-rubella Ab concentrations (IU/mL) Cohort 2', 'timeFrame': '28 days after the 12 month routine vaccinations', 'description': 'Antibody titers 28 days after the 12 month routine vaccinations'}, {'measure': 'Descriptive: Anti-varicella Ab concentrations (gpELISA units/mL)', 'timeFrame': '28 days after the 12 month routine vaccinations', 'description': 'Antibody titers 28 days after the 12 month routine vaccinations'}, {'measure': 'RSV A serum neutralizing antibody titers by baseline serostatus at Day 1 Cohort 1 and Cohort 2', 'timeFrame': 'Day 1', 'description': 'Antibody titers at Day 1'}, {'measure': 'RSV B serum neutralizing antibody titers by baseline serostatus at Day 1 Cohort 1 and Cohort 2', 'timeFrame': 'Day 1', 'description': 'Antibody titers at Day 1'}, {'measure': 'RSV A serum neutralizing antibody titers by baseline serostatus 28 days post-dose 2 1 Cohort 1 and Cohort 2', 'timeFrame': '28 days post-dose 2', 'description': 'Antibody titers 28 days post-dose 2'}, {'measure': 'RSV B serum neutralizing antibody titers by baseline serostatus 28 days post-dose 2 Cohort 1 and Cohort 2', 'timeFrame': '28 days post-dose 2', 'description': 'Antibody titers 28 days post-dose 2'}, {'measure': 'Presence of solicited administration site reactions within 21 days after each investigational medicinal product (IMP) administration Cohort 1 and Cohort 2', 'timeFrame': '21 days after each IMP administration', 'description': 'Number of participants experiencing solicited administration site reactions'}, {'measure': 'Presence of solicited systemic reactions within 21 days after each IMP administration Cohort 1 and Cohort 2', 'timeFrame': '21 days after each IMP administration', 'description': 'Number of participants experiencing solicited systemic site reactions'}, {'measure': 'Presence of unsolicited systemic adverse events (AEs) reported in the 30 minutes after each study intervention administration Cohort 1 and Cohort 2', 'timeFrame': 'Within 30 minutes after each study intervention administration', 'description': 'Number of participants experiencing unsolicited systemic adverse events'}, {'measure': 'Presence of unsolicited AEs within 28 days after each study intervention administration Cohort 1 and Cohort 2', 'timeFrame': 'Within 28 days after each study intervention administration', 'description': 'Number of participants experiencing unsolicited AEs'}, {'measure': 'Presence of medically attended adverse events (MAAEs) throughout the study Cohort 1 and Cohort 2', 'timeFrame': 'Throughout the study, approximately 9 months', 'description': 'Number of participants experiencing MAAEs'}, {'measure': 'Presence of serious adverse events (SAEs) throughout the study Cohort 1 and Cohort 2', 'timeFrame': 'Throughout the study, approximately 9 months', 'description': 'Number of participants experiencing SAEs'}, {'measure': 'Presence of adverse events of special interest (AESIs) throughout the study Cohort 1 and Cohort 2', 'timeFrame': 'Throughout the study, approximately 9 months', 'description': 'Number of participants experiencing AESIs'}]}, 'oversightModule': {'oversightHasDmc': True, 'isFdaRegulatedDrug': True, 'isFdaRegulatedDevice': False}, 'conditionsModule': {'conditions': ['RSV Immunization']}, 'descriptionModule': {'briefSummary': 'This study is a Phase III, randomized, single-blind, placebo-controlled, multi-center study to be conducted in healthy infants and toddlers which will be enrolled at approximately 6 months of age (Cohort 1) and approximately 12 months of age (Cohort 2). The primary objective of the study will be to assess non-inferiority of the RSV infant and toddler (RSVt) vaccine antibody response when administered concomitantly with routine pediatric vaccines at 6 months of age (Diphtheria and Tetanus Toxoids and Acellular Pertussis, Inactivated Poliovirus, Haemophilus b Conjugate and Hepatitis B Vaccine \\[Vaxelis® or Pentacel® and Recombivax HB®\\] Prevnar 20®, and RotaTeq®), and 12 months of age (M-M-R II, VARIVAX, and Prevnar 20 or per local country recommendations) compared to when administered non-concomitantly.', 'detailedDescription': 'The study duration is approximately 9 months for each participant.\n\n* Cohort 1: Visits at 6, 7, and 8 and 9 months of age for both groups with visit at 10 months of age for Group 2 only\n* Cohort 2: Visits at 12, 13, 14 and 15 months of age for both groups with visit at 16 months of age for Group 4 only\n* Routine pediatric vaccines (authorized auxiliary medicinal products (AxMP) will be administered at 6 months in Cohort 1 and 12 months of age in Cohort 2, as per Advisory Committee on Immunization Practice (ACIP) or local country recommendations.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['CHILD'], 'maximumAge': '12 Months', 'minimumAge': '6 Months', 'healthyVolunteers': True, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Aged 6 months for Cohort 1 and 12 months for Cohort 2 on the day of inclusion ("6 months" means from the day of the 6-month birthday to the day before the 7-month birthday and "12 months" means from the day of the 12-month birthday to the day before the 13-month birthday)\n* Participants who are healthy as determined by medical evaluation including medical history and physical examination\n* For Cohort 1: Infant received doses of vaccines containing hepatitis B, diphtheria, tetanus, pertussis, Haemophilus influenzae type B (Hib), and inactivated poliovirus vaccine (IPV) antigens, with Advisory Committee on Immunization Practice (ACIP) recommended vaccines. The last dose(s) of these vaccines must be at least 28 days before the first study visit\n* Infant received the recommended doses of a recommended pneumococcal conjugate vaccine (as per local schedule) at least 28 days before the first study visit.\n\nExclusion Criteria:\n\n* Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long-term systemic corticosteroid therapy (prednisone or equivalent for more than 2 consecutive weeks within the past 3 months)\n* Known previous infection with diphtheria, tetanus, Hib, measles, mumps, rubella, rotavirus, pneumococcus, polio, hepatitis B virus\n* Known systemic hypersensitivity to any of the study intervention components, or history of a life-threatening reaction to the study intervention used in the study or to a product containing any of the same substances\n* Chronic illness that, in the opinion of the investigator, is at a stage where it might interfere with study conduct or completion\n* History of medically diagnosed wheezing\n* Any acute febrile illness in the past 48 hours that according to investigator judgment is significant enough to interfere with successful inoculation on the day of vaccination. A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided.\n* Probable or confirmed ongoing case of viral respiratory infection (including COVID 19, influenza, rhinovirus, etc.) at the time of enrollment. A prospective participant should not be included in the study until the respiratory infection has resolved.\n* Member of a household that contains an immunocompromised individual, including, but not limited to:\n* A person living with human immunodeficiency virus (HIV)\n* A person who has received chemotherapy within the 12 months prior to study enrollment\n* A person who has received (within the past 6 months) or is receiving (at the time of enrollment) immunosuppressant agents\n* A person living with a solid organ or bone marrow transplant\n* Potential close contact with other immunocompromised individual within 30 days after each vaccination as per investigator\'s discretion\n* History of definitive contraindications to any of the concomitant vaccines that will be administered as part of the study protocol\n* Participant\'s biological mother with previous receipt or planned administration of an investigational RSV vaccine during pregnancy and/or breastfeeding\n* Receipt of any vaccine in the 4 weeks preceding RSVt vaccine administration or planned receipt of any vaccine outside of study protocol in the 4 weeks following RSVt vaccine administration, except for influenza and/or COVID-19 vaccination, which may be received at least 1 week before or 1 week after RSVt vaccine administration\n* Previous receipt of an investigational RSV vaccine or receiving any anti RSV product (such as ribavirin or RSV immune globulin) at the time of enrollment\n* Receipt of immune globulins, blood or blood-derived products in the past 3 months\n* Receipt of intranasal and intra-ocular medications within 3 days prior to study enrollment\n* Previous receipt of an RSV monoclonal antibody within 6 months prior to the first study vaccine administration or planned receipt for duration of the study\n* For Cohort 1: Prior receipt of routine 6-month pediatric vaccine doses (as per local schedule)\n* For Cohort 2: Prior receipt of routine 12-month pediatric vaccine doses (as per local schedule)\n* Participation at the time of study enrollment (or in the 6 weeks preceding the first study intervention administration) or planned participation during the present study period in another clinical study investigating a vaccine, drug, medical device, or medical procedure\n\nNote: The above information is not intended to contain all considerations relevant to a potential participation in a clinical trial.'}, 'identificationModule': {'nctId': 'NCT06397768', 'acronym': 'CORAL', 'briefTitle': 'Co-administration Study of an Investigational Live-Attenuated Respiratory Syncytial Virus Vaccine in Infants and Toddlers', 'organization': {'class': 'INDUSTRY', 'fullName': 'Sanofi'}, 'officialTitle': 'Phase III, Randomized, Single-blind, Placebo-controlled, Multi-center Study to Evaluate Non-interference of Concomitant Administration of Routine Pediatric Vaccines on the Antibody Response of an Investigational Live-attenuated Respiratory Syncytial Virus (RSV) Vaccine in Healthy Infants and Toddlers (CORAL)', 'orgStudyIdInfo': {'id': 'VAD00016'}, 'secondaryIdInfos': [{'id': 'VAD00016', 'type': 'OTHER', 'domain': 'Sanofi Identifier'}, {'id': 'U1111-1290-7356', 'type': 'REGISTRY', 'domain': 'ICTRP'}, {'id': '2024-000262-15', 'type': 'EUDRACT_NUMBER'}]}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'Cohort 1: Group 1- (RSVt vaccine concomitantly at 6 months)', 'description': 'Participants will be administered RSVt vaccine concomitantly with routine pediatric vaccines, 2 doses, at age 6 months. Vaccines administered at age 6 months: RSVt Vaxelis or Pentacel and Recombivax HB, Prevnar 20, and RotaTeq. Placebo will be administered non-concomitantly at 7 months of age', 'interventionNames': ['Biological: RSVt vaccine', 'Biological: Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine', 'Biological: Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine', 'Biological: Hepatitis B vaccine', 'Biological: Streptococcus pneumoniae vaccine', 'Biological: Rotavirus vaccine', 'Biological: Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'Cohort 1: Group 2- (RSVt vaccine non-concomitantly at 7 months)', 'description': 'Participants will be administered RSVt vaccine non-concomitantly with routine pediatric vaccines, 2 doses, at age 7 months. Vaccines administered at age 6 months: Vaxelis or Pentacel and Recombivax HB, Prevnar 20, and RotaTeq. Placebo will be administered concomitantly at 6 months of age', 'interventionNames': ['Biological: RSVt vaccine', 'Biological: Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine', 'Biological: Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine', 'Biological: Hepatitis B vaccine', 'Biological: Streptococcus pneumoniae vaccine', 'Biological: Rotavirus vaccine', 'Biological: Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'Cohort 2: Group 3- (RSVt vaccine concomitantly at 12 months)', 'description': 'Participants will be administered RSVt vaccine concomitantly with routine pediatric vaccines, 2 doses, at age 12 months. Vaccines administered at age 6 months: M-M-R II, VARIVAX, and Prevnar 20. Placebo will be administered non-concomitantly at 13 months of age', 'interventionNames': ['Biological: RSVt vaccine', 'Biological: Streptococcus pneumoniae vaccine', 'Biological: Measles, mumps, and rubella vaccine', 'Biological: Varicella virus vaccine', 'Biological: Placebo']}, {'type': 'EXPERIMENTAL', 'label': 'Cohort 2: Group 4- (RSVt vaccine non-concomitantly at 13 months)', 'description': 'Participants will be administered RSVt vaccine non-concomitantly with routine pediatric vaccines, 2 doses, at age 13 months. Vaccines administered at age 6 months: M-M-R II, VARIVAX, and Prevnar 20. Placebo will be administered concomitantly at 12 months of age', 'interventionNames': ['Biological: RSVt vaccine', 'Biological: Streptococcus pneumoniae vaccine', 'Biological: Measles, mumps, and rubella vaccine', 'Biological: Varicella virus vaccine', 'Biological: Placebo']}], 'interventions': [{'name': 'RSVt vaccine', 'type': 'BIOLOGICAL', 'otherNames': ['534'], 'description': 'Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal', 'armGroupLabels': ['Cohort 1: Group 1- (RSVt vaccine concomitantly at 6 months)', 'Cohort 1: Group 2- (RSVt vaccine non-concomitantly at 7 months)', 'Cohort 2: Group 3- (RSVt vaccine concomitantly at 12 months)', 'Cohort 2: Group 4- (RSVt vaccine non-concomitantly at 13 months)']}, {'name': 'Diphtheria, tetanus, pertussis, poliomyelitis , Haemophilus influenzae type b, and hepatitis B vaccine', 'type': 'BIOLOGICAL', 'otherNames': ['Vaxelis®'], 'description': 'Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular', 'armGroupLabels': ['Cohort 1: Group 1- (RSVt vaccine concomitantly at 6 months)', 'Cohort 1: Group 2- (RSVt vaccine non-concomitantly at 7 months)']}, {'name': 'Diphtheria, tetanus, pertussis, Haemophilus influenzae type b and poliomyelitis vaccine', 'type': 'BIOLOGICAL', 'otherNames': ['Pentacel®'], 'description': 'Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular', 'armGroupLabels': ['Cohort 1: Group 1- (RSVt vaccine concomitantly at 6 months)', 'Cohort 1: Group 2- (RSVt vaccine non-concomitantly at 7 months)']}, {'name': 'Hepatitis B vaccine', 'type': 'BIOLOGICAL', 'otherNames': ['RECOMBIVAX HB® or alternate monovalent hepatitis B vaccine'], 'description': 'Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular', 'armGroupLabels': ['Cohort 1: Group 1- (RSVt vaccine concomitantly at 6 months)', 'Cohort 1: Group 2- (RSVt vaccine non-concomitantly at 7 months)']}, {'name': 'Streptococcus pneumoniae vaccine', 'type': 'BIOLOGICAL', 'otherNames': ['PREVNAR 20®'], 'description': 'Pharmaceutical form:Suspension for injection-Route of administration:Intramuscular', 'armGroupLabels': ['Cohort 1: Group 1- (RSVt vaccine concomitantly at 6 months)', 'Cohort 1: Group 2- (RSVt vaccine non-concomitantly at 7 months)', 'Cohort 2: Group 3- (RSVt vaccine concomitantly at 12 months)', 'Cohort 2: Group 4- (RSVt vaccine non-concomitantly at 13 months)']}, {'name': 'Rotavirus vaccine', 'type': 'BIOLOGICAL', 'otherNames': ['RotaTeq®'], 'description': 'Pharmaceutical form:Oral solution-Route of administration:Oral', 'armGroupLabels': ['Cohort 1: Group 1- (RSVt vaccine concomitantly at 6 months)', 'Cohort 1: Group 2- (RSVt vaccine non-concomitantly at 7 months)']}, {'name': 'Measles, mumps, and rubella vaccine', 'type': 'BIOLOGICAL', 'otherNames': ['M-M-R® II'], 'description': 'Pharmaceutical form:Lyophilized live virus for reconstitution -Route of administration:Subcutaneous or Intramuscular', 'armGroupLabels': ['Cohort 2: Group 3- (RSVt vaccine concomitantly at 12 months)', 'Cohort 2: Group 4- (RSVt vaccine non-concomitantly at 13 months)']}, {'name': 'Varicella virus vaccine', 'type': 'BIOLOGICAL', 'otherNames': ['VARIVAX®'], 'description': 'Pharmaceutical form:Suspension for injection-Route of administration:Subcutaneous or Intramuscular', 'armGroupLabels': ['Cohort 2: Group 3- (RSVt vaccine concomitantly at 12 months)', 'Cohort 2: Group 4- (RSVt vaccine non-concomitantly at 13 months)']}, {'name': 'Placebo', 'type': 'BIOLOGICAL', 'description': 'Pharmaceutical form:Liquid for nasal spray-Route of administration:Intranasal', 'armGroupLabels': ['Cohort 1: Group 1- (RSVt vaccine concomitantly at 6 months)', 'Cohort 1: Group 2- (RSVt vaccine non-concomitantly at 7 months)', 'Cohort 2: Group 3- (RSVt vaccine concomitantly at 12 months)', 'Cohort 2: Group 4- (RSVt vaccine non-concomitantly at 13 months)']}]}, 'contactsLocationsModule': {'locations': [{'zip': '35205', 'city': 'Birmingham', 'state': 'Alabama', 'country': 'United States', 'facility': "Alabama Clinical Therapeutics - Birmingham - St. Vincent's Drive- Site Number : 8400007", 'geoPoint': {'lat': 33.52066, 'lon': -86.80249}}, {'zip': '36541', 'city': 'Grand Bay', 'state': 'Alabama', 'country': 'United States', 'facility': 'South Alabama Medical Clinic- Site Number : 8400065', 'geoPoint': {'lat': 30.47631, 'lon': -88.34223}}, {'zip': '36608', 'city': 'Mobile', 'state': 'Alabama', 'country': 'United States', 'facility': 'MedPharmics - Mobile - Dauphin Street- Site Number : 8400017', 'geoPoint': {'lat': 30.69436, 'lon': -88.04305}}, {'zip': '72703', 'city': 'Fayetteville', 'state': 'Arkansas', 'country': 'United States', 'facility': 'Northwest Arkansas Pediatric Clinic- Site Number : 8400002', 'geoPoint': {'lat': 36.06258, 'lon': -94.15743}}, {'zip': '90201', 'city': 'Bell Gardens', 'state': 'California', 'country': 'United States', 'facility': 'Alliance Research Institute- Site Number : 8400040', 'geoPoint': {'lat': 33.96529, 'lon': -118.15146}}, {'zip': '90255', 'city': 'Huntington Park', 'state': 'California', 'country': 'United States', 'facility': 'Matrix Clinical Research - Huntington Park- Site Number : 8400018', 'geoPoint': {'lat': 33.98168, 'lon': -118.22507}}, {'zip': '91942', 'city': 'La Mesa', 'state': 'California', 'country': 'United States', 'facility': 'Paradigm Clinical Research Centers- Site Number : 8400059', 'geoPoint': {'lat': 32.76783, 'lon': -117.02308}}, {'zip': '90057', 'city': 'Los Angeles', 'state': 'California', 'country': 'United States', 'facility': 'Matrix Clinical Research - Los Angeles- Site Number : 8400008', 'geoPoint': {'lat': 34.05223, 'lon': -118.24368}}, {'zip': '94611', 'city': 'Oakland', 'state': 'California', 'country': 'United States', 'facility': 'Kaiser Permanente - Oakland Medical Center- Site Number : 8400047', 'geoPoint': {'lat': 37.80437, 'lon': -122.2708}}, {'zip': '95661', 'city': 'Roseville', 'state': 'California', 'country': 'United States', 'facility': 'Kaiser Permanente - Sierra Gardens- Site Number : 8400063', 'geoPoint': {'lat': 38.75212, 'lon': -121.28801}}, {'zip': '95815', 'city': 'Sacramento', 'state': 'California', 'country': 'United States', 'facility': 'Kaiser Permanente - Point West Medical Offices- Site Number : 8400064', 'geoPoint': {'lat': 38.58157, 'lon': -121.4944}}, {'zip': '95119', 'city': 'San Jose', 'state': 'California', 'country': 'United States', 'facility': 'Kaiser Permanente - San Jose Medical Center- Site Number : 8400060', 'geoPoint': {'lat': 37.33939, 'lon': -121.89496}}, {'zip': '95051', 'city': 'Santa Clara', 'state': 'California', 'country': 'United States', 'facility': 'Kaiser Permanente - Santa Clara- Site Number : 8400061', 'geoPoint': {'lat': 37.35411, 'lon': -121.95524}}, {'zip': '91356', 'city': 'Tarzana', 'state': 'California', 'country': 'United States', 'facility': 'Integrated Clinical Research- Site Number : 8400036', 'geoPoint': {'lat': 34.17334, 'lon': -118.55397}}, {'zip': '94596', 'city': 'Walnut Creek', 'state': 'California', 'country': 'United States', 'facility': 'Kaiser Permanente - Walnut Creek Medical Center- Site Number : 8400062', 'geoPoint': {'lat': 37.90631, 'lon': -122.06496}}, {'zip': '20016', 'city': 'Washington D.C.', 'state': 'District of Columbia', 'country': 'United States', 'facility': 'Velocity Clinical Research - Washington DC- Site Number : 8400050', 'geoPoint': {'lat': 38.89511, 'lon': -77.03637}}, {'zip': '33021', 'city': 'Hollywood', 'state': 'Florida', 'country': 'United States', 'facility': 'The Medici Medical Research- Site Number : 8400055', 'geoPoint': {'lat': 26.0112, 'lon': -80.14949}}, {'zip': '33126', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Dade Research Center- Site Number : 8400014', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '33133', 'city': 'Miami', 'state': 'Florida', 'country': 'United States', 'facility': 'Riveldi Biomedical Research and Associates - Miami- Site Number : 8400015', 'geoPoint': {'lat': 25.77427, 'lon': -80.19366}}, {'zip': '32503', 'city': 'Pensacola', 'state': 'Florida', 'country': 'United States', 'facility': 'SEC Clinical Research- Site Number : 8400034', 'geoPoint': {'lat': 30.42131, 'lon': -87.21691}}, {'zip': '33613', 'city': 'Tampa', 'state': 'Florida', 'country': 'United States', 'facility': 'PAS Research- Site Number : 8400005', 'geoPoint': {'lat': 27.94752, 'lon': -82.45843}}, {'zip': '83404', 'city': 'Idaho Falls', 'state': 'Idaho', 'country': 'United States', 'facility': "Leavitt Women's Healthcare- Site Number : 8400009", 'geoPoint': {'lat': 43.46658, 'lon': -112.03414}}, {'zip': '51106', 'city': 'Sioux City', 'state': 'Iowa', 'country': 'United States', 'facility': 'Velocity Clinical Research - Sioux City- Site Number : 8400054', 'geoPoint': {'lat': 42.49999, 'lon': -96.40031}}, {'zip': '67042', 'city': 'El Dorado', 'state': 'Kansas', 'country': 'United States', 'facility': 'Alliance for Multispeciality Research - El Dorado- Site Number : 8400019', 'geoPoint': {'lat': 37.81724, 'lon': -96.86225}}, {'zip': '40536', 'city': 'Lexington', 'state': 'Kentucky', 'country': 'United States', 'facility': 'University of Kentucky Chandler Medical Center- Site Number : 8400051', 'geoPoint': {'lat': 37.98869, 'lon': -84.47772}}, {'zip': '70119', 'city': 'New Orleans', 'state': 'Louisiana', 'country': 'United States', 'facility': 'Velocity Clinical Researchâ€" New Orleans- Site Number : 8400058', 'geoPoint': {'lat': 29.95465, 'lon': -90.07507}}, {'zip': '70125', 'city': 'New Orleans', 'state': 'Louisiana', 'country': 'United States', 'facility': 'NOLA Research Works- Site Number : 8400044', 'geoPoint': {'lat': 29.95465, 'lon': -90.07507}}, {'zip': '39531', 'city': 'Biloxi', 'state': 'Mississippi', 'country': 'United States', 'facility': 'MedPharmics - Biloxi- Site Number : 8400011', 'geoPoint': {'lat': 30.39603, 'lon': -88.88531}}, {'zip': '65802', 'city': 'Springfield', 'state': 'Missouri', 'country': 'United States', 'facility': 'QPS Bio-Kinetic Clinical Applications- Site Number : 8400046', 'geoPoint': {'lat': 37.21533, 'lon': -93.29824}}, {'zip': '59405', 'city': 'Great Falls', 'state': 'Montana', 'country': 'United States', 'facility': 'Boeson Research - Great Falls- Site Number : 8400041', 'geoPoint': {'lat': 47.50024, 'lon': -111.30081}}, {'zip': '59804', 'city': 'Missoula', 'state': 'Montana', 'country': 'United States', 'facility': 'Boeson Research - Missoula- Site Number : 8400006', 'geoPoint': {'lat': 46.87215, 'lon': -113.994}}, {'zip': '68901', 'city': 'Hastings', 'state': 'Nebraska', 'country': 'United States', 'facility': 'Velocity Clinical Research - Hastings- Site Number : 8400016', 'geoPoint': {'lat': 40.58612, 'lon': -98.38839}}, {'zip': '68516', 'city': 'Lincoln', 'state': 'Nebraska', 'country': 'United States', 'facility': 'Midwest Childrens Health Research Institute- Site Number : 8400038', 'geoPoint': {'lat': 40.8, 'lon': -96.66696}}, {'zip': '68134', 'city': 'Omaha', 'state': 'Nebraska', 'country': 'United States', 'facility': 'Velocity Clinical Research - Omaha- Site Number : 8400001', 'geoPoint': {'lat': 41.25626, 'lon': -95.94043}}, {'zip': '89014', 'city': 'Henderson', 'state': 'Nevada', 'country': 'United States', 'facility': 'PAS Research- Site Number : 8400049', 'geoPoint': {'lat': 36.0397, 'lon': -114.98194}}, {'zip': '13088', 'city': 'Liverpool', 'state': 'New York', 'country': 'United States', 'facility': 'Summerwood Pediatrics- Site Number : 8400021', 'geoPoint': {'lat': 43.10646, 'lon': -76.2177}}, {'zip': '13210', 'city': 'Syracuse', 'state': 'New York', 'country': 'United States', 'facility': 'SUNY Upstate Medical University - Syracuse- Site Number : 8400029', 'geoPoint': {'lat': 43.04812, 'lon': -76.14742}}, {'zip': '45406', 'city': 'Dayton', 'state': 'Ohio', 'country': 'United States', 'facility': 'Dayton Clinical Research- Site Number : 8400030', 'geoPoint': {'lat': 39.75895, 'lon': -84.19161}}, {'zip': '45414', 'city': 'Dayton', 'state': 'Ohio', 'country': 'United States', 'facility': 'Ohio Pediatrics - Dayton- Site Number : 8400033', 'geoPoint': {'lat': 39.75895, 'lon': -84.19161}}, {'zip': '44121', 'city': 'South Euclid', 'state': 'Ohio', 'country': 'United States', 'facility': 'Senders Pediatrics- Site Number : 8400022', 'geoPoint': {'lat': 41.52311, 'lon': -81.51846}}, {'zip': '97030', 'city': 'Gresham', 'state': 'Oregon', 'country': 'United States', 'facility': 'Cyn3rgy Research- Site Number : 8400053', 'geoPoint': {'lat': 45.49818, 'lon': -122.43148}}, {'zip': '16506', 'city': 'Erie', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Square-1 Clinical Research- Site Number : 8400031', 'geoPoint': {'lat': 42.12922, 'lon': -80.08506}}, {'zip': '15227', 'city': 'Pittsburgh', 'state': 'Pennsylvania', 'country': 'United States', 'facility': 'Pas Research - Pittsburgh- Site Number : 8400043', 'geoPoint': {'lat': 40.44062, 'lon': -79.99589}}, {'zip': '29607', 'city': 'Greenville', 'state': 'South Carolina', 'country': 'United States', 'facility': 'Tribe Clinical Research - 525 Verdae Boulevard- Site Number : 8400012', 'geoPoint': {'lat': 34.85262, 'lon': -82.39401}}, {'zip': '78413', 'city': 'Corpus Christi', 'state': 'Texas', 'country': 'United States', 'facility': 'South Texas Clinical Research- Site Number : 8400004', 'geoPoint': {'lat': 27.80058, 'lon': -97.39638}}, {'zip': '75230', 'city': 'Dallas', 'state': 'Texas', 'country': 'United States', 'facility': 'Javara - Privia Medical Group North Texas - Dallas- Site Number : 8400003', 'geoPoint': {'lat': 32.78306, 'lon': -96.80667}}, {'zip': '78539', 'city': 'Edinburg', 'state': 'Texas', 'country': 'United States', 'facility': 'PAS RESEARCH- Site Number : 8400035', 'geoPoint': {'lat': 26.30174, 'lon': -98.16334}}, {'zip': '76104', 'city': 'Fort Worth', 'state': 'Texas', 'country': 'United States', 'facility': 'Ventavia Research Group - Fort Worth- Site Number : 8400020', 'geoPoint': {'lat': 32.72541, 'lon': -97.32085}}, {'zip': '77008', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Ventavia Research Group - Houston - North Loop West- Site Number : 8400010', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '77030', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'UTHealth Houston- Site Number : 8400037', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '77065', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'DM Clinical Research - Houston - Jones Road- Site Number : 8400052', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '77070', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Mercury Clinical Research - Houston - Savoy Drive- Site Number : 8400045', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '77071', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Chemidox Clinical Trials- Site Number : 8400039', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '77090', 'city': 'Houston', 'state': 'Texas', 'country': 'United States', 'facility': 'Houston Clinical Research Associates- Site Number : 8400013', 'geoPoint': {'lat': 29.76328, 'lon': -95.36327}}, {'zip': '77555', 'city': 'League City', 'state': 'Texas', 'country': 'United States', 'facility': 'University of Texas Medical Branch at Galveston- Site Number : 8400057', 'geoPoint': {'lat': 29.50745, 'lon': -95.09493}}, {'zip': '77573', 'city': 'League City', 'state': 'Texas', 'country': 'United States', 'facility': 'Maximos Ob/Gyn- Site Number : 8400024', 'geoPoint': {'lat': 29.50745, 'lon': -95.09493}}, {'zip': '75093', 'city': 'Plano', 'state': 'Texas', 'country': 'United States', 'facility': 'Research Your Health- Site Number : 8400066', 'geoPoint': {'lat': 33.01984, 'lon': -96.69889}}, {'zip': '77469', 'city': 'Richmond', 'state': 'Texas', 'country': 'United States', 'facility': 'Pediatric Center - Richmond- Site Number : 8400032', 'geoPoint': {'lat': 29.58218, 'lon': -95.76078}}, {'zip': '77375', 'city': 'Tomball', 'state': 'Texas', 'country': 'United States', 'facility': 'North Houston Internal Medicine and Pediatric Center- Site Number : 8400025', 'geoPoint': {'lat': 30.09716, 'lon': -95.61605}}, {'zip': '84057', 'city': 'Orem', 'state': 'Utah', 'country': 'United States', 'facility': 'Utah Valley Pediatrics - Orem- Site Number : 8400067', 'geoPoint': {'lat': 40.2969, 'lon': -111.69465}}, {'zip': '84404', 'city': 'Pleasant View', 'state': 'Utah', 'country': 'United States', 'facility': 'Ogden Clinic - Mountain View - CCT Research- Site Number : 8400056', 'geoPoint': {'lat': 41.31828, 'lon': -111.99216}}, {'zip': '04530', 'city': 'Mexico City', 'state': 'Mexico City', 'country': 'Mexico', 'facility': 'Investigational Site Number : 4840001', 'geoPoint': {'lat': 19.42847, 'lon': -99.12766}}, {'zip': '62587', 'city': 'Temixco', 'state': 'Morelos', 'country': 'Mexico', 'facility': 'Investigational Site Number : 4840002', 'geoPoint': {'lat': 18.85254, 'lon': -99.22537}}, {'zip': '06760', 'city': 'Mexico City', 'country': 'Mexico', 'facility': 'Investigational Site Number : 4840004', 'geoPoint': {'lat': 19.42847, 'lon': -99.12766}}, {'zip': '00725', 'city': 'Caguas', 'country': 'Puerto Rico', 'facility': 'Investigational Site Number : 6300001', 'geoPoint': {'lat': 18.23412, 'lon': -66.0485}}, {'zip': '00716', 'city': 'Ponce', 'country': 'Puerto Rico', 'facility': 'Investigational Site Number : 6300003', 'geoPoint': {'lat': 18.01031, 'lon': -66.62398}}, {'zip': '00976', 'city': 'Trujillo Alto', 'country': 'Puerto Rico', 'facility': 'Investigational Site Number : 6300004', 'geoPoint': {'lat': 18.35467, 'lon': -66.00739}}]}, 'ipdSharingStatementModule': {'ipdSharing': 'YES', 'description': "Qualified researchers may request access to patient level data and related study documents including the clinical study report, study protocol with any amendments, blank case report form, statistical analysis plan, and dataset specifications. Patient level data will be anonymized and study documents will be redacted to protect the privacy of trial participants. Further details on Sanofi's data sharing criteria, eligible studies, and process for requesting access can be found at: https://vivli.org"}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Sanofi Pasteur, a Sanofi Company', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}